BRIGHT MINDS BIOSCIENCES INC.

Overview

Compare with another stock.

• TickerDRUG on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersChicago, Illinois¹
• Incorporated inBritish Columbia, Canada³
• Business address400 N Aberdeen St Suite 900, Chicago, Il 60642³
• Filer category, Emerging growth company³
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Additional information related us is available on SEDAR+ at www.sedarplus.ca and on our website at https://brightmindsbio.com/ . We do not incorporate the contents of our website or of www.sedarplus.ca into this Annual Report. Information on our website does not constitute part of this Annual Report. In addition, the SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC which can be viewed as www.sec.gov .⁴ From its latest annual report

Corporate structure

BRIGHT MINDS BIOSCIENCES INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What BRIGHT MINDS BIOSCIENCES INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

• President, Chief Executive Officer and DirectorIan McDonald named May 3, 2022 to Nov 19, 2024⁹
• Chief Scientific Officer and DirectorJan Torleif Pedersen named Sep 1, 2022 to Nov 19, 2024⁹
• Chief Financial Officer and Corporate SecretaryRyan Cheung named May 3, 2022 to Nov 19, 2024⁹
• Chief Science OfficerJAN CHRISTIAN PEDERSEN named May 3, 2024 to Oct 22, 2024¹⁰
• Chief Medical OfficerMARK SMITH named May 3, 2024¹¹
• Chief Medical OfficerRevati Shreeniwas named Sep 1, 2022 to Sep 14, 2022¹²
• Executive OfficerGideon Shapiro named May 3, 2022¹³
• Executive OfficerRevati Sheeniwas named May 3, 2022¹³
• DirectorDavid M Weiner named Nov 19, 2024⁹
• DirectorJeremy M Fryzuk named May 3, 2022 to Nov 19, 2024⁹
• DirectorNils M Bottler named May 3, 2022 to Nov 19, 2024⁹
• DirectorDAVID CHRISTIAN WEINER named May 3, 2024 to Oct 22, 2024¹⁰
• DirectorJEREMY CHRISTIAN FRYZUK named May 3, 2024 to Oct 22, 2024¹⁰
• DirectorNILS CHRISTIAN BOTTLER named May 3, 2024 to Oct 22, 2024¹⁰
• DirectorDouglas Williamson named Sep 14, 2022¹²
• DirectorNils Torleif Bottler named Sep 1, 2022 to Sep 14, 2022¹²
• DirectorAlan Kozikowski named May 3, 2022 to Sep 1, 2022¹⁴
• DirectorJan Pedersen named May 3, 2022¹³

Calendar

Drug trials and FDA: coming up

1. Nov 2026Phase 2 trial readout expected Phase 2 trial of BMB-101 in Prader-Willi Syndrome: primary completion expected Nov 2026 (ClinicalTrials.gov NCT07266324).¹⁵

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

154 filings to the SEC since October 2021: 6 annual reports, 4 insider forms, 38 large holders, 7 private raises, 99 other. The latest 20:

1. Oct 2, 20266-K EDGAR
2. Oct 1, 20266-K EDGAR
3. Aug 17, 20266-K EDGAR
4. Aug 14, 2026SCHEDULE 13G/A EDGAR
5. Aug 13, 2026S-8 EDGAR
6. Aug 12, 2026SCHEDULE 13G/A EDGAR
7. Jul 2, 2026SCHEDULE 13D/A EDGAR
8. Jun 3, 20266-K EDGAR
9. Jun 2, 20266-K EDGAR
10. May 28, 20266-K EDGAR
11. May 20, 20266-K EDGAR
12. May 15, 2026SCHEDULE 13G/A EDGAR
13. May 15, 2026SCHEDULE 13G/A EDGAR
14. May 15, 2026SCHEDULE 13G EDGAR
15. May 12, 2026SCHEDULE 13G/A EDGAR
16. Apr 30, 2026SCHEDULE 13G/A EDGAR
17. Apr 30, 20264 EDGAR
18. Feb 17, 2026SCHEDULE 13G/A EDGAR
19. Feb 17, 2026SCHEDULE 13G/A EDGAR
20. Feb 17, 2026SCHEDULE 13G/A EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 3 buys and 1 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Cormorant Asset Management, LPSCHEDULE 13G/A, 5 filings Oct 22, 2024 to Aug 14, 2026¹⁶
• Adage Capital Management, L.P.SCHEDULE 13G/A, 2 filings Nov 13, 2025 to Aug 12, 2026¹⁷
• Ian McDonaldSCHEDULE 13D/A, 6 filings Jan 18, 2024 to Jul 2, 2026¹⁸
• Janus Henderson Group Ltd.SCHEDULE 13G/A, 6 filings Feb 7, 2025 to May 15, 2026¹⁹
• Vestal Point Capital, LPSCHEDULE 13G, 1 filing May 15, 2026²⁰
• Vivo Opportunity Fund Holdings, L.P.SCHEDULE 13G/A, 2 filings Nov 14, 2025 to May 12, 2026²¹
• Commodore Capital LPSCHEDULE 13G/A, 3 filings Oct 25, 2024 to Feb 17, 2026²²
• PERCEPTIVE ADVISORS LLCSCHEDULE 13G/A, 3 filings Oct 16, 2024 to Feb 17, 2026²³
• Sio Capital Management, LLCSCHEDULE 13G/A, 4 filings Feb 10, 2025 to Nov 12, 2025²⁴
• RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13G/A, 2 filings Nov 12, 2024 to May 15, 2025²⁵
• Point72 Asset Management, L.P.SCHEDULE 13G/A, 2 filings Oct 23, 2024 to Feb 14, 2025²⁶
• Logos Global Management LPSC 13G, 1 filing Oct 23, 2024²⁷
• PFM Health Sciences, LPSC 13G/A, 1 filing Oct 22, 2024²⁸

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Nov 4, 2024Raised $34.6 million in a private offering of equity⁹ Form D: 13 investors so far Form D
2. Oct 3, 2024Filed a private offering of securities¹⁰ Form D: $12,186 offered in all Form D
3. Mar 22, 2024Filed a private offering of equity¹¹ Form D: $54,160 offered in all Form D
4. Sep 6, 2022Filed a private offering of securities¹² Form D: $149,784 offered in all Form D
5. Aug 30, 2022Filed a private offering of equity¹⁴ Form D: $220,329 offered in all Form D
6. Feb 11, 2022Raised $82,667 in a private offering of equity²⁹ Form D: 1 investor so far Form D
7. Feb 4, 2022Raised $59,765 in a private offering of equity¹³ Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How BRIGHT MINDS BIOSCIENCES INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARBRIGHT MINDS BIOSCIENCES INC.¹
• CIK0001827401
• Filer status<br>emerging growth company an emerging growth company¹
• Incorporated inBritish Columbia³⁰
• Fiscal year endsSeptember 30¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address400 N Aberdeen St Suite 900, Chicago, IL 60642¹
• Phone6474072515¹
• Shares outstanding4,524,087 as of Sep 30, 2024²
• AuditorDe Visser Gray LLP PCAOB ID 1054; no auditor attestation of internal control over financial reporting³⁰
• On EDGAR sinceOct 6, 2020¹
• Filings179 in all: 6-K (85), SCHEDULE 13G/A (18), D (14), UPLOAD (7), CORRESP (6), SC 13G (6), SCHEDULE 13G (6), 20-F (4)¹
  All 28 form types

  20FR12G/A (4), SC 13D/A (4), 4 (3), 424B5 (2), EFFECT (2), F-3 (2), FWP (2), SC 13G/A (2), 20-F/A (1), 20FR12G (1), 3 (1), 40-F (1), 424B3 (1), 6-K/A (1), 8-A12B (1), CERT (1), F-X (1), S-8 (1), SC 13D (1), SCHEDULE 13D/A (1)

• Latest filingsAnnual report (40-F) Dec 23, 2025

Securities registered for trading

From the cover page of the 40-F filed Dec 23, 2025 (Section 12(b) of the Exchange Act).³⁰